Towards engineering hormone-binding globulins as drug delivery agents.

The treatment of many diseases such as cancer requires the use of drugs that can cause severe side effects. Off-target toxicity can often be reduced simply by directing the drugs specifically to sites of diseases. Amidst increasingly sophisticated methods of targeted drug delivery, we observed that...

Full description

Saved in:
Bibliographic Details
Main Authors: Wee Lee Chan, Aiwu Zhou, Randy J Read
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2014-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0113402
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849332501851406336
author Wee Lee Chan
Aiwu Zhou
Randy J Read
author_facet Wee Lee Chan
Aiwu Zhou
Randy J Read
author_sort Wee Lee Chan
collection DOAJ
description The treatment of many diseases such as cancer requires the use of drugs that can cause severe side effects. Off-target toxicity can often be reduced simply by directing the drugs specifically to sites of diseases. Amidst increasingly sophisticated methods of targeted drug delivery, we observed that Nature has already evolved elegant means of sending biological molecules to where they are needed. One such example is corticosteroid binding globulin (CBG), the major carrier of the anti-inflammatory hormone, cortisol. Targeted release of cortisol is triggered by cleavage of CBG's reactive centre loop by elastase, a protease released by neutrophils in inflamed tissues. This work aimed to establish the feasibility of exploiting this mechanism to carry therapeutic agents to defined locations. The reactive centre loop of CBG was altered with site-directed mutagenesis to favour cleavage by other proteases, to alter the sites at which it would release its cargo. Mutagenesis succeeded in making CBG a substrate for either prostate specific antigen (PSA), a prostate-specific serine protease, or thrombin, a key protease in the blood coagulation cascade. PSA is conspicuously overproduced in prostatic hyperplasia and is, therefore, a good way of targeting hyperplastic prostate tissues. Thrombin is released during clotting and consequently is ideal for conferring specificity to thrombotic sites. Using fluorescence-based titration assays, we also showed that CBG can be engineered to bind a new compound, thyroxine-6-carboxyfluorescein, instead of its physiological ligand, cortisol, thereby demonstrating that it is possible to tailor the hormone binding site to deliver a therapeutic drug. In addition, we proved that the efficiency with which CBG releases bound ligand can be increased by introducing some well-placed mutations. This proof-of-concept study has raised the prospect of a novel means of targeted drug delivery, using the serpin conformational change to combat the problem of off-target effects in the treatment of diseases.
format Article
id doaj-art-ffbe437eb51f4e6d8ae821b9b304c1a1
institution Kabale University
issn 1932-6203
language English
publishDate 2014-01-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS ONE
spelling doaj-art-ffbe437eb51f4e6d8ae821b9b304c1a12025-08-20T03:46:11ZengPublic Library of Science (PLoS)PLoS ONE1932-62032014-01-01911e11340210.1371/journal.pone.0113402Towards engineering hormone-binding globulins as drug delivery agents.Wee Lee ChanAiwu ZhouRandy J ReadThe treatment of many diseases such as cancer requires the use of drugs that can cause severe side effects. Off-target toxicity can often be reduced simply by directing the drugs specifically to sites of diseases. Amidst increasingly sophisticated methods of targeted drug delivery, we observed that Nature has already evolved elegant means of sending biological molecules to where they are needed. One such example is corticosteroid binding globulin (CBG), the major carrier of the anti-inflammatory hormone, cortisol. Targeted release of cortisol is triggered by cleavage of CBG's reactive centre loop by elastase, a protease released by neutrophils in inflamed tissues. This work aimed to establish the feasibility of exploiting this mechanism to carry therapeutic agents to defined locations. The reactive centre loop of CBG was altered with site-directed mutagenesis to favour cleavage by other proteases, to alter the sites at which it would release its cargo. Mutagenesis succeeded in making CBG a substrate for either prostate specific antigen (PSA), a prostate-specific serine protease, or thrombin, a key protease in the blood coagulation cascade. PSA is conspicuously overproduced in prostatic hyperplasia and is, therefore, a good way of targeting hyperplastic prostate tissues. Thrombin is released during clotting and consequently is ideal for conferring specificity to thrombotic sites. Using fluorescence-based titration assays, we also showed that CBG can be engineered to bind a new compound, thyroxine-6-carboxyfluorescein, instead of its physiological ligand, cortisol, thereby demonstrating that it is possible to tailor the hormone binding site to deliver a therapeutic drug. In addition, we proved that the efficiency with which CBG releases bound ligand can be increased by introducing some well-placed mutations. This proof-of-concept study has raised the prospect of a novel means of targeted drug delivery, using the serpin conformational change to combat the problem of off-target effects in the treatment of diseases.https://doi.org/10.1371/journal.pone.0113402
spellingShingle Wee Lee Chan
Aiwu Zhou
Randy J Read
Towards engineering hormone-binding globulins as drug delivery agents.
PLoS ONE
title Towards engineering hormone-binding globulins as drug delivery agents.
title_full Towards engineering hormone-binding globulins as drug delivery agents.
title_fullStr Towards engineering hormone-binding globulins as drug delivery agents.
title_full_unstemmed Towards engineering hormone-binding globulins as drug delivery agents.
title_short Towards engineering hormone-binding globulins as drug delivery agents.
title_sort towards engineering hormone binding globulins as drug delivery agents
url https://doi.org/10.1371/journal.pone.0113402
work_keys_str_mv AT weeleechan towardsengineeringhormonebindingglobulinsasdrugdeliveryagents
AT aiwuzhou towardsengineeringhormonebindingglobulinsasdrugdeliveryagents
AT randyjread towardsengineeringhormonebindingglobulinsasdrugdeliveryagents